日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Reply to Schön et al., "Quality control and considering systematic MIC shifts are key when evaluating the role of mmpR5 (Rv0678) frameshifts in bedaquiline resistance"

回复 Schön 等人，“在评估 mmpR5 (Rv0678) 移码突变在贝达喹啉耐药性中的作用时，质量控制和考虑系统性 MIC 变化是关键”

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00317-25
Snobre, J; Meehan, C J; Mulders, W; Rigouts, L; Buyl, R; de Jong, B C; Van Rie, A; Tzfadia, O
发表日期：2025
文献求助 收藏

High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial

在全口服利福平耐药结核病治疗的第一周使用高剂量阿米卡星是安全的：一项单臂试验

期刊:
影响因子:
doi:10.5588/ijtldopen.25.0120
Snobre, J; Gasana, J; Decroo, T; Mucyo, Y; Jacobs, B K M; Rigouts, L; Martin, I C; Herssens, N; Hakizayezu, F; Ntihumbya, J B; Kilibazayire, A; de Viron, E; Runyambo, D; Ndayishimiye, C; Merle, C S; Muvunyi, C M; Migambi, P; Sturkenboom, M G G; de Jong, B C; Ngabonziza, J C S
发表日期：2025
文献求助 收藏

Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis

mmpR5基因的移码突变可通过保留与野生型结核分枝杆菌相似的蛋白质结构和功能，产生对贝达喹啉敏感的表型。

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00854-24
Snobre, J; Meehan, C J; Mulders, W; Rigouts, L; Buyl, R; de Jong, B C; Van Rie, A; Tzfadia, O
发表日期：2024
文献求助 收藏

Single nucleotide variation catalog from clinical isolates mapped on tertiary and quaternary structures of ESX-1-related proteins reveals critical regions as putative Mtb therapeutic targets

将临床分离株的单核苷酸变异目录映射到ESX-1相关蛋白的三级和四级结构上，揭示了关键区域作为潜在的结核分枝杆菌治疗靶点。

期刊:Microbiology Spectrum
影响因子:3.8
doi:10.1128/spectrum.03816-23
Tzfadia, Oren; Gijsbers, Abril; Vujkovic, Alexandra; Snobre, Jihad; Vargas, Roger; Dewaele, Klaas; Meehan, Conor J; Farhat, Maha; Hakke, Sneha; Peters, Peter J; de Jong, Bouke C; Siroy, Axel; Ravelli, Raimond B G
发表日期：2024
文献求助 收藏

Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial

在全口服利福平耐药结核病治疗的第一周使用高剂量阿米卡星预防获得性耐药的安全性（STAKE）：单臂临床试验方案

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2023-078379
Snobre, Jihad; Gasana, Joel; Ngabonziza, Jean Claude Semuto; Cuella-Martin, Isabel; Rigouts, Leen; Jacobs, Bart Karl; de Viron, Emeline; Herssens, Natacha; Ntihumby, Jean Baptiste; Klibazayre, Annualithe; Ndayishimiye, Clement; Van Deun, Armand; Affolabi, Dissou; Merle, Corinne S; Muvunyi, Claude; Sturkenboom, Marieke G G; Migambi, Patrick; de Jong, Bouke C; Mucyo, Yves; Decroo, Tom
发表日期：2024
文献求助 收藏